Single domain antibodies: a new approach in therapeutics

Mahesh Narkhede*, Rohan Narkhede, Mangesh Mapari

Department of Pharmacology, Dr Rajendra Gode College of Pharmacy, Malkapur, Maharashtra, India

Refer this article

Mahesh Narkhede, Rohan Narkhede, Mangesh Mapari, 2017. Single domain antibodies: a new approach in therapeutics. Journal of medical pharmaceutical and allied sciences, V 6 - I 5, Pages -567 – 571. Doi: https://doi.org/10.55522/jmpas.V6I5.0150.

ABSTRACT

Single domain antibodies are rapidly comes into therapeutics in last two decades due to their therapeutic advantages. Most of drugs are derived from antibodies based proteins. Single domain antibodies having advantages over the monoclonal antibodies such as small size, heat resistant, stability, hydrophobicity, low immunogenicity, high solubility. These are small in size hence called nobodies. Their production is carried outing mammalian cells for therapeutic uses. These single domain antibodies are now employed in drug delivery system. They are also utilized in identification of toxin. Single domain antibodies are recently employed in treatment diseases like cancer, Alzheimer’s disease, Parkinson’s disease etc. They are also employed in virus detection.This is a cross sectional and correlational-descriptive study conducted among 197 nurses working in Golestan Hospital of Ahvaz. Moslach Burnout Inventory (MBIQ) and General Health Questionnaire (GHQ) were instruments for data collection. SPSS software was applied for analyzing the data.

Keywords:

Single domain antibodies, Nano bodies, Polymer some, Complementarity, ADCC, Multimerization.

Full Text Article